Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eradication of Minimal Residual Disease (MRD) in Patients With Chronic Lymphocytic Leukaemia (CLL) With Alemtuzumab: A Phase II Study

NCT00458523 is registered in ClinicalTrials.gov with Leeds Cancer Centre at St. James's University Hospital as lead sponsor.

NCT NCT00458523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00458523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eradication of Minimal Residual Disease (MRD) in Patients With Chronic Lymphocytic Leukaemia (CLL) With Alemtuzumab: A Phase II Study
Lead sponsor
Leeds Cancer Centre at St. James's University Hospital
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
February 29, 2008
Enrollment
54 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia